GlassScriptPhysician profile
Jon F Scheiber
NPI 1417963737
$4,291.70
in general payments reported to CMS, 2019-2025
26 companies · $1,011 in 2025
The $1,011 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $819 · 2020: $179 · 2021: $274 · 2022: $55.27 · 2023: $827 · 2024: $1,128 · 2025: $1,011.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,966.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,965.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $694.72 | 2019-2024 | Xarelto |
| Abbott Laboratories | $528.62 | 2019-2025 | Cardiomems |
| Amgen INC. | $433.58 | 2019-2025 | Repatha, Repatha |
| Actelion Pharmaceuticals US, INC. | $404.23 | 2024-2025 | Opsumit, Uptravi |
| Novartis Pharmaceuticals Corporation | $377.14 | 2019-2025 | |
| Pfizer INC. | $267.50 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $263.60 | 2019-2025 | Wainua, Farxiga |
| Boehringer Ingelheim Pharmaceuticals, INC. | $262.97 | 2019-2025 | Jardiance |
| E.R. Squibb & Sons, L.L.C. | $229.10 | 2019-2023 | Camzyos |
| Novo Nordisk INC | $189.48 | 2024-2025 | Wegovy, Rybelsus, Ozempic |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $111.31 | 2019-2024 | Lifevest |
| Kiniksa Pharmaceuticals, LTD. | $61.93 | 2022-2023 | Arcalyst |
| Regeneron Healthcare Solutions, INC. | $61.26 | 2019-2023 | Evkeeza |
| Alnylam Pharmaceuticals INC. | $61.00 | 2021 | |
| Kiniksa Pharmaceuticals International, Plc | $51.46 | 2024 | Arcalyst |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $43.06 | 2024-2025 | Verquvo |
| Preventice Services, LLC | $38.89 | 2019 | |
| Baxter Healthcare | $37.93 | 2025 | Hillrom - Carnation Ambulatory Monitor |
| Bridgebio Pharma, INC. | $32.55 | 2025 | Attruby |
| Lexicon Pharmaceuticals, INC. | $29.77 | 2024 | |
| Boston Scientific Corporation | $29.25 | 2019 | |
| Medtronic Vascular, INC. | $21.32 | 2019 | |
| Impulse Dynamics (USA) INC. | $17.70 | 2023 | Optimizer |
| Sanofi-Aventis U.S. LLC | $16.60 | 2020 | |
| Bardy Diagnostics, INC. | $14.36 | 2021 | |
| Amarin Pharma, INC. | $12.37 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jon Scheiber listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.